Completed PHASE3 INTERVENTIONAL 2-arm NCT00925587

Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease

A Multicenter, Randomised, Double-Blind Study Comparing De Novo Once Monthly and Once Every 2 Week Darbepoetin Alfa Dosing for the Correction of Anemia in Subjects With Chronic Kidney Disease Not Receiving Dialysis

Sponsor: Amgen

Conditions Anemia Chronic Kidney Disease

Interventions darbepoetin alfa

Updated 6 times since 2017 Last updated: May 15, 2014 Started: Jun 30, 2009 Primary completion: Apr 30, 2012 Completion: May 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Anemia and Chronic Kidney Disease and is currently completed. Amgen leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albano Laziale RM, Italy , Alexandroupoli, Greece , Ancona, Italy , Annonay, France , Ashkelon, Israel , Athens, Greece , Baja, Hungary , Barcelona, Spain , Belgrade, Serbia , Bernkastel-Kues, Germany and 128 more locations